Skovronsky Daniel 4

4 · ELI LILLY & Co · Filed Feb 12, 2025

Form 4

Period: 2025-02-10

EVP, CS&PO & Pres. LRL

Transactions

Sale
Common Stock
2025-02-10$862.69/sh−3,950$3,407,626→ 118,938.36 total
Sale
Common Stock
2025-02-10$863.97/sh−340$293,750→ 118,598.36 total
Sale
Common Stock
2025-02-10$865.76/sh−710$614,690→ 117,888.36 total
Award
Common Stock
2025-02-10$868.88/sh+18,771.752$16,310,400→ 136,660.112 total
Award
Restricted Stock Unit
2025-02-10+12,684→ 12,684 total
From: 2026-02-01Exp: 2026-02-01→ Common Stock (12,684 underlying)

Holdings

Footnotes (4)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2024.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F3]The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
[F4]Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

Documents

1 file